Generics - Abbott Laboratories


Current filters:

Abbott Laboratories

Popular Filters

Abbott spends $2.9 billion on CFR Pharma to expand Latin American presence


US drugmaker Abbott has signed an agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals,…

Abbott LaboratoriesCFR PharmaceuticalsGenericsMergers & AcquisitionsSouth America

Abbott may acquire one of Russia’s leading drugmakers for $240 million


The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s…

Abbott LaboratoriesGenericsMergers & AcquisitionsRussiaVeropharm

US FDA warns pregnant women to not use valproate migraine prevention medicines


The US Food and Drug Administration is alerting health care providers and patients that medications including…

Abbott LaboratoriesGenericsNeurologicalNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationSanofivalproate Sodium Injection

Biosimilars threaten to burst Humira's blockbuster bubble


US health care major Abbott Laboratories' (NYSE: ABT) Humira (adalimumab) has a strong reputation as…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGenericsHumiraMarkets & Marketing

AET BioTech and BioXpress to co-develop biosimilar Humira


Plans to develop another biosimilar version of Abbott Laboratories blockbuster rheumatoid arthritis drug…

Abbott LaboratoriesadalimumabAET BioTechAnti-Arthritics/RheumaticsBiotechnologyBioXpress TherapeuticsGenericsHumiraProductionResearch

FTC seeks US Supreme Court review in AndroGel "pay-for-delay" case


At the request of the US Federal Trade Commission, the Solicitor General of the USA petitioned the country's…

Abbott LaboratoriesAndroGelGenericsLegalMen's HealthNorth AmericaPatentsPharmaceuticalSolvayWatson Pharmaceuticals

Watson confirms Abbott Niaspan patent challenge


USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

Abbott LaboratoriesCardio-vascularGenericsNiaspanNorth AmericaPatentsWatson Pharmaceuticals

Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine


A global campaign to challenge US health care major Abbott Laboratories’ (NYSE: ABT) monopolistic…

Abbott LaboratoriesAnti-viralsGenericsGlobalKaletra CapsulesPharmaceuticalPricing

Back to top